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147 Segregation of children 5 and under diagnosed via newborn
screening does not prevent acquisition of P. aeruginosa
K. McKay1, P. Cooper1, P. van Asperen1. 1The Children’s Hospital at Westmead,
Westmead, NSW, Australia
In recent years, transmissible strains of P. aeruginosa (PsA) have been described.
Data from the Wisconsin newborn screening (NBS) study have shown that infants
are at risk of early PsA acquisition from older patients. We have had NBS since
1981 and in May 2003, reorganised our CF service so that children 5 yrs were
‘segregated’ for outpatient and inpatient care. This study investigated the effect of
this change on the acquisition of respiratory pathogens. The results of all sputum
cultures (n = 2814 cultures in total) for all children 5 yrs before (1999–2002) and
after (2004–2007) ‘segregation’ were collected. Each year 72−90 children of this
age were seen and each child provided an average of 4.6 suction samples for culture
per year. The % of children with one or more sputum cultures positive for pathogens
of interest in the 4 years before and after ‘segregation’ are shown.
There was a signiﬁcant decrease (p0.001, c2) in the acquisition of mucoid but
not non-mucoid PsA after ‘segregation’. The apparent increase in acquisition of H.
inﬂuenzae was related to a change in microbiological detection processes during
this period. These results suggest that young children diagnosed via NBS may be
protected from the acquisition of mucoid PsA from older children by ‘segregation’
and that the acquisition of non-mucoid PsA in young children is from sources
outside the hospital environment, but other factors also need consideration.
Before ‘segregation’ After ‘segregation’
E. coli 40.7 39.8
H. inﬂuenzae 5.2 14.3
S. aureus 45.5 50.1
MRSA 1.3 1.0
non-mucoid PsA 22.3 22.7
mucoid PsA 5.9 1.0
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Background: Currently, initial respiratory infection with P. aeruginosa (PA) is
treated with aggressive antibiotic therapy. However at this stage tissue destruction
by PA, accompanying pulmonary inﬂammatory response and adaptation of PA might
have already occurred; eradication is not always achieved.
Prophylactic antibiotic therapy seemed to have a preventive effect in small and
retrospective studies, but has not been proven prospectively in a controlled manner.
Hypothesis: Prophylactic treatment of PA-negative CF patients will prevent or delay
the ﬁrst acquisition of PA or eradicate PA before the onset of persistent colonization
and accompanying pulmonary inﬂammatory response.
Methods: Sixty-eight children (age 0.3−17.0; mean 7.3 y) without PA infection
from 4 CF-centres were randomly allocated to 3-monthly courses of 3 weeks oral
ciproﬂoxacin (10mg/kg bid) and inhaled colistin (1 MIU bid) or both matching
placebos during 3 years. Patients, investigators and doctors were blinded for
allocation. Patients regularly visited the clinic for evaluation of PA- and clinical
status. PA-status was determined by culturing sputa or cough swabs 3-monthly and
measuring anti-PA antibodies 6-monthly.
The primary endpoint is initial PA infection (2 PA-positive cultures taken 1 week
apart or 1 positive culture with pulmonary exacerbation). Secondary endpoints
are PA-free interval, anti-PA antibodies, respiratory pathogens, antibiotic use and
resistance, number of exacerbations, adverse events, pulmonary function, chest
X-ray scores, inﬂammation parameters and BMI.
Results: Trial results (ISRCTN11604593), available May 2009, will be presented
and discussed.
Supported by: NCFS.
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Objective: To analyze the genetic background of the ﬁrst P. aeruginosa isolate
detected colonizing cystic ﬁbrosis (CF) patients attended in our CF-Unit from 1994
to 2007.
Patients and Methods: Twenty-one CF patients (median age 9 years, range 0−34)
were included. From these patients, only the ﬁrst P. aeruginosa isolate detected were
selected. Antibiotic susceptibility was determined using the agar dilution method,
following the CLSI guidelines. To study the genetic background, both PFGE-SpeI
and MLST (Curran et al. 2004, http://pubmlst.org/paeruginosa) experiments were
performed in all isolates.
Results: Median follow-up period of these patients were 6.9 years (range 1−14).
Percentages of susceptible isolate to different antimicrobials were as follows:
colistin 96%, meropenem 95%, tobramycin 88%, ciproﬂoxacin 88%, ceftazidime
83% imipenem 79% piperacillin-tazobactam 76%, and amikacin 63%. SpeI-PFGE
identiﬁed 19 unrelated pulsotypes, and also 2 patients presented related isolates.
Moreover, 20 different sequence types (STs) were identiﬁed within studied isolates.
A group of 3 patients carried single locus variants.
Conclusions: Unlike other studies, a polyclonal structure of P. aeruginosa from
initial colonization stages in CF patients were observed without detected identiﬁed
epidemic clones.
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Background: The occurrence of highly prevalent Pseudomonas aeruginosa clones
reported in CF centres around the world has lead to the implementation of strict
segregation measures. The clinical impact of such strains however remains unclear.
Recently, MLST typing of P. aeruginosa isolates revealed a highly prevalent clone
in the population of the CF centre in Utrecht, The Netherlands, designated ST406.
We aimed to study whether carriage of this clone was associated with impaired
lung function or a different BMI.
Methods: Respiratory tract colonization status was determined in 334 CF patients
(from a total population of 359 patients) during 2007 and 148 (44%) carried
P. aeruginosa, of which 33 (22%) carried ST406. Demographic, genetic and clinical
parameters were obtained from all 148 patients colonized with P. aeruginosa, in
order to determine associations between patients colonized with either ST406 or
non-ST406 strains.
Results: In preliminary analyses carriage of ST406 was not associated with
FEV1% pred (p = 0.28), FVC% pred (p = 0.53) and BMI (p = 0.11). Furthermore,
there appeared to be no association between ST406 and genetic or demographic
parameters.
Conclusion: Carriage of the highly prevalent P. aeruginosa clone ST406 by patients
attending the largest CF centre in the Netherlands appears not to be associated with
impaired lung function or changed BMI.
